Ghareeb, Doaa ASaleh, Samar RNofal, Mohammed SKaddah, Mohamed M. YHassan, Salma. FSeif, Inas KEl-Zahaby, Sally AKhedr, Shaimaa MKenawy, Marwa YMasoud, Aliaa ASoudi, Salma ASobhy, Ahmed ASery, Jaillan GAbd El-Wahab, Miral GAbd Elmoneam, Alshimaa AAl-mahallawi, Abdulaziz MohsenEl-Demellawy, Maha A2021-03-162021-03-1603/05/20212093555210.1007/s40005-021-00520-4https://doi.org/http://repository.msa.edu.eg/xmlui/handle/123456789/4461ScopusBackground At the end of 2019, the new Coronavirus disease 2019 (COVID-19) strain causing severe acute respiratory syndrome swept the world. From November 2019 till February 2021, this virus infected nearly 104 million, with more than two million deaths and about 25 million active cases. This has prompted scientists to discover efective drugs to combat this pandemic. Area covered Drug repurposing is the magic bullet for treating severe acute respiratory syndrome coronavirus 2 (SARSCoV2). Therefore, several drugs have been investigated in silico, in vitro, as well as through human trials such as antiSARS-CoV2 agents, or to prevent the complications resulting from the virus. In this review, the mechanisms of action of diferent therapeutic strategies are summarized. According to the WHO, diferent classes of drugs can be used, including anti-malarial, antiviral, anti-infammatory, and anti-coagulant drugs, as well as angiotensin-converting enzyme inhibitors, antibiotics, vitamins, zinc, neutralizing antibodies, and convalescent plasma therapy. Recently, there are some vaccines which are approved against SARS-CoV2. Expert opinion A complete understanding of the structure and function of all viral proteins that play a fundamental role in viral infection, which contribute to the therapeutic intervention and the development of vaccine in order to reduce the mortality rate.en-USCOVID-19 HydroxychloroquineIndomethacin Tocilizumab Teicoplanin CamostatArticlehttps://doi.org/